45 results on '"Sharma, P."'
Search Results
2. Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and cyclophosphamide (SWOG S9313)
3. 822P Phase II clinical trial: Safety and efficacy study of tocilizumab (Toci) in combination with ipilimumab (Ipi) 3mg/kg plus nivolumab (Nivo) 1mg/kg in patients (pts) with metastatic melanoma (MM)
4. 265P Phase II study of DHP107 oral paclitaxel compared to IV paclitaxel in patients with HER2-negative recurrent or metastatic breast cancer (MBC): Opera (NCT03326102)
5. 1761MO Defining subset-wise myeloid responses to immune checkpoint blockade in melanoma
6. 678P Cytoreductive nephrectomy (CN) for patients with metastatic sarcomatoid and/or rhabdoid (S/R) renal cell carcinoma (RCC) treated with immune checkpoint inhibitors (ICI)
7. Last but not least: antibody–drug conjugates in hormone receptor-positive metastatic breast cancer
8. 349TiP EPIK-B3: A phase III, randomised, double-blind (DB), placebo (PBO)-controlled study of alpelisib (ALP) + nab-paclitaxel (nab-PTX) in advanced triple-negative breast cancer (TNBC) with either PIK3CA mutation or phosphatase and tensin homolog (PTEN) loss without PIK3CA mutation
9. 715P Immune checkpoint therapy (ICT) re-challenge after immune-related adverse events (irAEs) in genitourinary cancers (GUC)
10. 749P Nivolumab (N) alone or in combination with ipilimumab (I) in patients (pts) with platinum-pretreated metastatic urothelial carcinoma (mUC): Extended follow-up from CheckMate 032
11. Corrigendum to “Differential expression of various miRNAs in pediatric cytogenetically normal acute myeloid leukemia (CN-AML)”
12. A pilot study of tremelimumab (treme) with or without cryoablation (cryo) in patients (pts) in metastatic renal cell carcinoma (mRCC)
13. Randomized, open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC
14. Differential expression of various miRNAs in pediatric cytogenetically normal acute myeloid leukemia (CN-AML)
15. Role of post lasix FDG PETCT in recurrent carcinoma bladder
16. Nivolumab (N) alone or in combination with ipilimumab (I) in patients (pts) with platinum-pretreated metastatic urothelial carcinoma (mUC), including the nivolumab 1 mg/kg + ipilimumab 3 mg/kg expansion from CheckMate 032
17. Neoadjuvant vs. adjuvant chemotherapy for cholangiocarcinoma: A propensity score matched analysis
18. Prognostic significance of serum Beta 2 Microglobulin in Non-Hodgkin Lymphoma
19. Impact of zumor mutation burden on nivolumab efficacy in second-line urothelial carcinoma patients: Exploratory analysis of the phase ii checkmate 275 study
20. Nivolumab (NIVO) in patients (pts) with advanced (adv) chemotherapy-refractory (CT-Rx) esophagogastric (EG) cancer according to microsatellite instability (MSI) status: checkmate 032
21. Outcomes of patients with metastatic renal cell carcinoma (mRCC) who were treated with second-line (2L) vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKI) after first-line (1L) immune checkpoint inhibitor (ICI) therapy
22. LBA47 - Randomized, open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC
23. 963P - A pilot study of tremelimumab (treme) with or without cryoablation (cryo) in patients (pts) in metastatic renal cell carcinoma (mRCC)
24. 161P - Differential expression of various miRNAs in pediatric cytogenetically normal acute myeloid leukemia (CN-AML)
25. Updated results from a phase I study of nivolumab (Nivo) in combination with ipilimumab (Ipi) in metastatic renal cell carcinoma (mRCC): The CheckMate 016 study
26. Efficacy and safety of nivolumab monotherapy in patients with metastatic urothelial cancer (mUC) who have received prior treatment: Results from the phase II CheckMate 275 study
27. Nivolumab monotherapy in metastatic urothelial cancer (mUC): Updated efficacy by subgroups and safety results from the CheckMate 032 study
28. PD-009 - Randomized, open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC
29. 238P - Role of post lasix FDG PETCT in recurrent carcinoma bladder
30. LBA32 - Nivolumab (N) alone or in combination with ipilimumab (I) in patients (pts) with platinum-pretreated metastatic urothelial carcinoma (mUC), including the nivolumab 1 mg/kg + ipilimumab 3 mg/kg expansion from CheckMate 032
31. 763P - Neoadjuvant vs. adjuvant chemotherapy for cholangiocarcinoma: A propensity score matched analysis
32. 33P - Prognostic significance of serum Beta 2 Microglobulin in Non-Hodgkin Lymphoma
33. 891P - Outcomes of patients with metastatic renal cell carcinoma (mRCC) who were treated with second-line (2L) vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKI) after first-line (1L) immune checkpoint inhibitor (ICI) therapy
34. 848PD - Impact of zumor mutation burden on nivolumab efficacy in second-line urothelial carcinoma patients: Exploratory analysis of the phase ii checkmate 275 study
35. 674P - Nivolumab (NIVO) in patients (pts) with advanced (adv) chemotherapy-refractory (CT-Rx) esophagogastric (EG) cancer according to microsatellite instability (MSI) status: checkmate 032
36. Finite Androgen Deprivation Therapy (Adt) Plus Ipilimumab (Ipi) in Men with Hormone-Naïve Metastatic Prostate Cancer (Hn-Mpca)
37. Phase I Study of Nivolumab in Combination with Ipilimumab in Metastatic Renal Cell Carcinoma (Mrcc)
38. Nivolumab (N) (Anti-Pd-1; Bms-936558, Ono-4538) in Combination with Sunitinib (S) or Pazopanib (P) in Patients (Pts) with Metastatic Renal Cell Carcinoma (Mrcc)
39. Effect of Comorbidity on Surgery and Survival Among Lung Cancer Patients in England
40. LBA31_PR - Efficacy and safety of nivolumab monotherapy in patients with metastatic urothelial cancer (mUC) who have received prior treatment: Results from the phase II CheckMate 275 study
41. 1062P - Updated results from a phase I study of nivolumab (Nivo) in combination with ipilimumab (Ipi) in metastatic renal cell carcinoma (mRCC): The CheckMate 016 study
42. 784P - Nivolumab monotherapy in metastatic urothelial cancer (mUC): Updated efficacy by subgroups and safety results from the CheckMate 032 study
43. 1053PD - Finite Androgen Deprivation Therapy (Adt) Plus Ipilimumab (Ipi) in Men with Hormone-Naïve Metastatic Prostate Cancer (Hn-Mpca)
44. 1052PD - Nivolumab (N) (Anti-Pd-1; Bms-936558, Ono-4538) in Combination with Sunitinib (S) or Pazopanib (P) in Patients (Pts) with Metastatic Renal Cell Carcinoma (Mrcc)
45. 1050O - Phase I Study of Nivolumab in Combination with Ipilimumab in Metastatic Renal Cell Carcinoma (Mrcc)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.